⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
APLLTD - Swing Trade Analysis with AI Signals
Back to ListSwing Trade Rating: 3.6
| Stock Code | APLLTD | Market Cap | 15,701 Cr. | Current Price | 798 ₹ | High / Low | 1,108 ₹ |
| Stock P/E | 35.4 | Book Value | 267 ₹ | Dividend Yield | 1.38 % | ROCE | 11.3 % |
| ROE | 9.68 % | Face Value | 2.00 ₹ | DMA 50 | 826 ₹ | DMA 200 | 901 ₹ |
| Chg in FII Hold | 0.19 % | Chg in DII Hold | -0.13 % | PAT Qtr | 179 Cr. | PAT Prev Qtr | 104 Cr. |
| RSI | 49.5 | MACD | -14.2 | Volume | 39,343 | Avg Vol 1Wk | 37,374 |
| Low price | 725 ₹ | High price | 1,108 ₹ | PEG Ratio | -10.7 | Debt to equity | 0.27 |
| 52w Index | 19.0 % | Qtr Profit Var | 15.6 % | EPS | 22.6 ₹ | Industry PE | 29.1 |
📊 APLLTD shows moderate potential for swing trading. The current price (798 ₹) is below both the 50 DMA (826 ₹) and 200 DMA (901 ₹), reflecting short-term weakness. RSI at 49.5 indicates neutrality, while MACD (-14.2) suggests bearish momentum. Fundamentals are average with ROCE (11.3%) and ROE (9.68%), but the recent quarterly profit improvement (179 Cr vs 104 Cr) provides positive sentiment. Valuation is slightly high with P/E (35.4) compared to industry average (29.1).
✅ Optimal Entry Price: Around 770–785 ₹ (near support zone close to 725 ₹).
📈 Exit Strategy: If already holding, consider exiting near 850–880 ₹ (resistance around DMA levels) or set a stop-loss below 740 ₹.
Positive
- Quarterly profit growth (179 Cr vs 104 Cr) shows strong earnings momentum.
- EPS of 22.6 ₹ supports profitability.
- Dividend yield of 1.38% provides passive income.
- FII holdings increased slightly (+0.19%), reflecting some institutional confidence.
Limitation
- Price trading below DMA levels signals weak short-term momentum.
- ROCE (11.3%) and ROE (9.68%) are relatively low compared to peers.
- PEG ratio (-10.7) indicates poor valuation relative to growth prospects.
- Debt-to-equity ratio of 0.27 is manageable but higher than ideal for pharma sector.
Company Negative News
- No major external negative news reported